Pulse Biosciences, Inc.

PRESS RELEASE: Pulse Biosciences Announces Publication in the Journal of Thoracic and Cardiovascular Surgery We are excited to announce the publication of preclinical data showcasing the safety and efficacy of the nano-PFA Cardiac Surgical System in The Journal of Thoracic and Cardiovascular Surgery. The study demonstrates that nano-PFA technology rapidly creates durable, transmural cardiac lesions without collateral tissue damage, validating the expected clinical benefits of nano-PFA energy. For more information about the study, please view the press release at https://lnkd.in/gBJGGgy2 or the publication at https://lnkd.in/gBHz2dUa .

Great presentation by Dr. Stefano Spiezia on nanosecond Pulsed Field Ablation (nano-PFA) technology at the American Thyroid Association 2024 Conference. If you have any questions or would like to meet Dr. Spiezia, please stop by booth #506. #nanoPFA #pulsebiosciences #minimallyinvasive #ATA2024 Pulse Biosciences Website: https://lnkd.in/gSG38bxs

PRESS RELEASE: PULSE BIOSCIENCES ANNOUNCES APPOINTMENT OF DAVID KENIGSBERG, M.D. AS CHIEF MEDICAL OFFICER OF ELECTROPHYSIOLOGY We are pleased to announce that Dr. David Kenigsberg has joined Pulse Biosciences as our Chief Medical Officer of Electrophysiology. Dr. Kenigsberg is a highly respected cardiac electrophysiologist with a profound commitment to advancing treatments for atrial fibrillation. Please click here to read the full press release: https://lnkd.in/gtBbxtmr

PRESS RELEASE: PULSE BIOSCIENCES ANNOUNCES APPOINTMENT OF DAVID KENIGSBERG, M.D. AS CHIEF MEDICAL OFFICER OF ELECTROPHYSIOLOGY We are pleased to announce that Dr. David Kenigsberg has joined Pulse Biosciences as our Chief Medical Officer of Electrophysiology. Dr. Kenigsberg is a highly respected cardiac electrophysiologist with a profound commitment to advancing treatments for atrial fibrillation. Please click here to read the full press release: https://lnkd.in/gtBbxtmr

We are pleased to share that Prof. Stefano Spiezia will be presenting on nanosecond Pulsed Field Ablation (nano-PFA) technology at the American Thyroid Association conference this week. Join us on October 31 at 9:10a.m. in the Oral Abstracts – Technology & Thyroid room to gain insights into the future of nano-PFA technology. #nanoPFA #pulsebiosciences #minimallyinvasive #ATA2024

Pulse Biosciences will be exhibiting at the American Thyroid Association 2024 conference in Chicago, from October 30th through November 1st. If you would like to learn about Nanosecond Pulsed Field Ablation (nano-PFA) technology and how it is changing minimally invasive procedures, please join us at Booth #506. #nanoPFA #pulsebiosciences #minimallyinvasive #ATA2024

PRESS RELEASE: Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors Link: https://lnkd.in/gQ3d3_kp

PRESS RELEASE: Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Link: https://lnkd.in/gxRYGfG6

PRESS RELEASE: Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences Link: https://lnkd.in/ghbH4tj8

Press Release: Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Pulse Biosciences has received Breakthrough Device Designation from the U.S. FDA for our CellFX® nsPFA Cardiac Surgery System for the ablation of cardiac tissue for the treatment of atrial fibrillation (AF). The CellFX nsPFA Cardiac Surgery System with Surgical Clamp, utilizing our proprietary nanosecond Pulsed Field Ablation (nsPFA) technology, is designed to produce durable, continuous transmural ablation lesions during cardiac surgery procedures for the treatment of atrial fibrillation. Based on pre-clinical studies, a single application of less than 2 seconds with the Surgical Clamp creates a consistent, transmural ablation, which is significantly faster, requiring approximately one-twentieth the time of currently available thermal ablation technologies. As Dr. Niv Ad, our Chief Science Officer, Cardiac Surgery, stated, “The theoretical benefits of short-duration, high-amplitude energy pulses with a nonthermal mechanism of action suggest the potential for a safer and more effective treatment.” The Breakthrough Devices Program is a voluntary program for certain medical devices with the potential to provide more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, such as atrial fibrillation. Our President and CEO, Burke Barrett added that, “We plan to fully leverage the benefits of this designation and have chosen to seek PMA approval to achieve a specific indication for the treatment of atrial fibrillation. We look forward to aligning with the FDA on a pivotal clinical trial design in the near-term and towards initiating our planned first-in-human cases in the Netherlands soon.” More details about the FDA Breakthrough Designation and additional commentary can be found in the press release: https://lnkd.in/gVttBeZu #PulseBiosciences #CellFX #nsPFA #CardiacSurgery #AtrialFibrillation #BreakthroughTechnology